Molecular mechanisms of resistance to HER2-targeted therapy

被引：2
|
作者：
Esteva, F. J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST CANCER RESEARCH | 2009年 / 11卷
关键词：
HUMAN-BREAST-CANCER; TRASTUZUMAB;
D O I：
10.1186/bcr2283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [21] Mechanisms of Resistance to HER2-targeted Therapies in HER2-amplified Uterine Serous Carcinoma, and Strategies to Overcome It
    Menderes, Gulden
    Lopez, Salvatore
    Han, Chanhee
    Altwerger, Gary
    Gysler, Stefan
    Varughese, Joyce
    Schwartz, Peter E.
    Santin, Alessandro D.
    DISCOVERY MEDICINE, 2018, 26 (141) : 39 - 50
  • [22] Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
    Lopez-Albaitero, Andres
    Xu, Hong
    Guo, Hongfen
    Wang, Linlin
    Wu, Zhihao
    Tran, Hoa
    Chandarlapaty, Sarat
    Scaltriti, Maurizio
    Janjigian, Yelena
    de Stanchina, Elisa
    Cheung, Nai-Kong V.
    ONCOIMMUNOLOGY, 2017, 6 (03):
  • [23] Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
    Zongbi Yi
    Guohua Rong
    Yanfang Guan
    Jin Li
    Lianpeng Chang
    Hui Li
    Binliang Liu
    Wenna Wang
    Xiuwen Guan
    Quchang Ouyang
    Lixi Li
    Jingtong Zhai
    Chunxiao Li
    Lifeng Li
    Xuefeng Xia
    Ling Yang
    Haili Qian
    Xin Yi
    Binghe Xu
    Fei Ma
    npj Breast Cancer, 6
  • [24] HER2-targeted therapy in colorectal cancer: a comprehensive review
    Benli, Yeliz
    Arikan, Helin
    Akbulut-caliskan, Ozge
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [25] Late cardiotoxicity related to HER2-targeted cancer therapy
    Isabelle Senechal
    Maria Sol Andres
    Jieli Tong
    Ylenia Perone
    Sivatharshini Ramalingam
    Muhummad Sohaib Nazir
    Stuart D Rosen
    Nicholas Turner
    Alistair Ring
    Alexander R Lyon
    Cardio-Oncology, 10
  • [26] Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
    Yi, Zongbi
    Rong, Guohua
    Guan, Yanfang
    Li, Jin
    Chang, Lianpeng
    Li, Hui
    Liu, Binliang
    Wang, Wenna
    Guan, Xiuwen
    Ouyang, Quchang
    Li, Lixi
    Zhai, Jingtong
    Li, Chunxiao
    Li, Lifeng
    Xia, Xuefeng
    Yang, Ling
    Qian, Haili
    Yi, Xin
    Xu, Binghe
    Ma, Fei
    NPJ BREAST CANCER, 2020, 6 (01)
  • [27] The gut microbiota contributes to the effectiveness of HER2-targeted therapy
    Di Modica, Martina
    Regondi, Viola
    Gargari, Giorgio
    Bonizzi, Arianna
    Arioli, Stefania
    Belmonte, Beatrice
    Tripodo, Claudio
    Guglielmetti, Simone
    Corsi, Fabio
    Triulzi, Tiziana
    Tagliabue, Elda
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Recent advances in HER2-targeted delivery for cancer therapy
    Dhritlahre, Rakesh Kumar
    Saneja, Ankit
    DRUG DISCOVERY TODAY, 2021, 26 (05) : 1319 - 1329
  • [29] Late cardiotoxicity related to HER2-targeted cancer therapy
    Senechal, Isabelle
    Andres, Maria Sol
    Tong, Jieli
    Perone, Ylenia
    Ramalingam, Sivatharshini
    Nazir, Muhummad Sohaib
    Rosen, Stuart D.
    Turner, Nicholas
    Ring, Alistair
    Lyon, Alexander R.
    CARDIO-ONCOLOGY, 2024, 10 (01)
  • [30] PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
    Zhang, Xianglan
    Park, Ji Soo
    Park, Kyu Hyun
    Kim, Ki Hyang
    Jung, Minkyu
    Chung, Hyun Cheol
    Rha, Sun Young
    Kim, Hyo Song
    ONCOLOGY, 2015, 88 (02) : 76 - 85
12345